Published in J Neurol on March 11, 2010
Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron (2012) 1.78
The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain (2011) 1.36
Therapeutics development in myotonic dystrophy type 1. Muscle Nerve (2011) 1.07
Myotonic dystrophy mouse models: towards rational therapy development. Trends Mol Med (2011) 1.07
White matter abnormalities and neurocognitive correlates in children and adolescents with myotonic dystrophy type 1: a diffusion tensor imaging study. Neuromuscul Disord (2010) 0.96
Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1. J Neurol (2012) 0.94
Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci (2014) 0.87
Cognitive impairment in myotonic dystrophy type 1 is associated with white matter damage. PLoS One (2014) 0.85
Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis. Cell Reprogram (2013) 0.82
Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2. J Neurol (2014) 0.81
Detection of slipped-DNAs at the trinucleotide repeats of the myotonic dystrophy type I disease locus in patient tissues. PLoS Genet (2013) 0.81
Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime Sleepiness. PLoS One (2015) 0.80
Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells. Stem Cells (2015) 0.80
Ocular Findings of Myotonic Dystrophy Type 1 in the Korean Population. Graefes Arch Clin Exp Ophthalmol (2016) 0.80
How genetics affects the brain to produce higher-level dysfunctions in myotonic dystrophy type 1. Funct Neurol (2015) 0.79
Comparisons of intellectual capacities between mild and classic adult-onset phenotypes of myotonic dystrophy type 1 (DM1). Orphanet J Rare Dis (2014) 0.79
Muscle wasting in myotonic dystrophies: a model of premature aging. Front Aging Neurosci (2015) 0.77
Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: A longitudinal case series study. Neuroradiol J (2016) 0.77
Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study. Orphanet J Rare Dis (2016) 0.76
In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8. BMC Neurol (2016) 0.76
Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2. Neurol Sci (2016) 0.76
Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. Neurol Sci (2017) 0.76
Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1. Neuroimage Clin (2016) 0.76
Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies. J Neurodegener Dis (2013) 0.75
Congenital myotonic dystrophy: ventriculomegaly and shunt considerations for the pediatric neurosurgeon. Childs Nerv Syst (2016) 0.75
Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell (1992) 12.74
Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science (2001) 7.34
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Anterior cingulate cortex and conflict detection: an update of theory and data. Cogn Affect Behav Neurosci (2007) 4.08
Function and localization within rostral prefrontal cortex (area 10). Philos Trans R Soc Lond B Biol Sci (2007) 1.88
Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. Arch Neurol (1998) 1.81
Prefrontal activity associated with working memory and episodic long-term memory. Neuropsychologia (2003) 1.73
Cerebral abnormalities in myotonic dystrophy. Cerebral blood flow, magnetic resonance imaging, and neuropsychological tests. Arch Neurol (1993) 1.73
Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol (1994) 1.68
Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med (1995) 1.64
Cerebral involvement in myotonic dystrophies. Muscle Nerve (2007) 1.57
Magnetic resonance imaging and clinical correlates of intellectual impairment in myotonic dystrophy. Arch Neurol (1989) 1.54
Genetic mapping of a second myotonic dystrophy locus. Nat Genet (1998) 1.52
Differential involvement of regions of rostral prefrontal cortex (Brodmann area 10) in time- and event-based prospective memory. Int J Psychophysiol (2006) 1.46
Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology (2001) 1.45
RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord (2004) 1.40
Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord (2003) 1.33
Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology (1994) 1.31
New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC). Neurology (2000) 1.24
Selective right parietal lobe activation during mental rotation: a parametric PET study. Brain (2000) 1.19
Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2. J Neurol (2004) 1.19
Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord (1997) 1.14
99mTc-ECD brain perfusion SPET: variability, asymmetry and effects of age and gender in healthy adults. Eur J Nucl Med (2001) 1.12
Central nervous system magnetic resonance imaging findings in myotonic dystrophy. Arch Neurol (1988) 1.03
Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. Neurology (1999) 1.03
Anterior temporal white matter lesions in myotonic dystrophy with intellectual impairment: an MRI and neuropathological study. Neuroradiology (1998) 1.03
Sustained and transient neural modulations in prefrontal cortex related to declarative long-term memory, working memory, and attention. Cortex (2007) 0.99
Cerebral atrophy in myotonic dystrophy: a voxel based morphometric study. J Neurol Neurosurg Psychiatry (2004) 0.99
Decreased cerebral glucose utilization in myotonic dystrophy. Neurology (1992) 0.98
Brain perfusion SPECT: age- and sex-related effects correlated with voxel-based morphometric findings in healthy adults. Radiology (2001) 0.97
Proximal myotonic myopathy with MRI white matter abnormalities of the brain. Neurology (1997) 0.96
Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging study. Neurosci Lett (2003) 0.95
Relationship between diffusion tensor imaging and brain morphology in patients with myotonic dystrophy. Neurosci Lett (2006) 0.94
Correlation among subcortical white matter lesions, intelligence and CTG repeat expansion in classic myotonic dystrophy type 1. Acta Neurol Scand (2008) 0.93
Autobiographical memory after temporal lobe resection: neuropsychological and MRI volumetric findings. Brain (2007) 0.92
Pattern and significance of white matter abnormalities in myotonic dystrophy type 1: an MRI study. J Neurol (2002) 0.92
Neuroimaging study of myotonic dystrophy. I. Magnetic resonance imaging of the brain. Brain Dev (1995) 0.89
Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1. Muscle Nerve (2006) 0.88
The clinical and genetic correlates of MRI findings in myotonic dystrophy. Neuroradiology (1996) 0.88
Brain MRI features of congenital- and adult-form myotonic dystrophy type 1: case-control study. Neuromuscul Disord (2002) 0.87
Cranial MRI findings in myotonic dystrophy. Neuroradiology (1997) 0.86
Dilated Virchow-Robin spaces in myotonic dystrophy: frequency, extent and significance. Eur Neurol (2001) 0.85
Diffusion tensor imaging of cerebral white matter in patients with myotonic dystrophy. Acta Radiol (2005) 0.84
Cortical damage in brains of patients with adult-form of myotonic dystrophy type 1 and no or minimal MRI abnormalities. J Neurol (2006) 0.83
Entorhinal cortex contributes to object-in-place scene memory. Eur J Neurosci (2004) 0.83
T2 relaxometry of brain in myotonic dystrophy. Neuroradiology (2001) 0.83
Involvement of the central nervous system in myotonic dystrophy. J Neurol Sci (1994) 0.83
Cognitive and neuroradiological findings in myotonic dystrophy. Funct Neurol (1992) 0.82
Impaired cerebral glucose metabolism in myotonic dystrophy: a triplet-size dependent phenomenon. Neuromuscul Disord (1998) 0.82
Familial aggregation of white matter lesions in myotonic dystrophy type 1. Neuromuscul Disord (2008) 0.81
White matter lesions and cognitive deficits: relevance of lesion pattern? Acta Neurol Scand (1994) 0.81
Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis. Clin Genet (2001) 0.81
Brain involvement in myotonic dystrophy: MRI features and their relationship to clinical and cognitive conditions. Acta Neurol Scand (1994) 0.81
Positron emission tomography in myotonic dystrophy. Psychiatry Res (1993) 0.81
Brain disease and molecular analysis in myotonic dystrophy. Neuroreport (1994) 0.80
Brain magnetic resonance image changes in a family with congenital and classic myotonic dystrophy. Brain Dev (2005) 0.80
Clinical and neuroimaging study of central nervous system in congenital myotonic dystrophy. J Neurol (1999) 0.78
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet (1997) 6.85
Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet (1998) 4.38
SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology (2010) 3.37
MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci U S A (1992) 2.82
Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet (1991) 2.79
Correlating phenotype and genotype in the periodic paralyses. Neurology (2004) 2.55
Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet (1995) 2.53
MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol (1992) 2.48
Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med (1989) 2.45
Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science (1973) 2.34
Fingerprint body myopathy, a newly recognized congenital muscle disease. Mayo Clin Proc (1972) 2.34
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology (2009) 2.33
Anti-ganglioside antibodies in children with coeliac disease: correlation with gluten-free diet and neurological complications. Aliment Pharmacol Ther (2004) 2.18
Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology (2010) 2.14
Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology (2011) 2.06
Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun (1995) 2.06
Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia (2007) 2.01
Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology (2005) 1.90
Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation. Hum Mol Genet (1995) 1.89
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer (2006) 1.84
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke (1996) 1.84
22q11 deletions in isolated and syndromic patients with tetralogy of Fallot. Hum Genet (1995) 1.82
Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther (2002) 1.82
Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med (1997) 1.82
Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology (1989) 1.81
MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol (2011) 1.76
Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: evidence of subclinical myogenic myopathy. J Am Coll Cardiol (1989) 1.76
Cerebellar ataxia and coenzyme Q10 deficiency. Neurology (2003) 1.73
Genetic localization of a new locus for recessive familial spastic paraparesis to 15q13-15. Neurology (1999) 1.72
Pulmonary inflammatory myofibroblastic tumour with unusual octreoscan uptake: two reports. Eur Respir J (2010) 1.68
Scan of human genome reveals no new Loci under ancient balancing selection. Genetics (2006) 1.68
Mutations in the hepatocyte nuclear factor-1beta gene are associated with familial hypoplastic glomerulocystic kidney disease. Am J Hum Genet (2000) 1.64
Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology (1995) 1.62
Linkage disequilibrium between cystic fibrosis and linked DNA polymorphisms in Italian families: a collaborative study. Am J Hum Genet (1988) 1.60
Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients. Neurol Sci (2010) 1.58
Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation (1996) 1.54
Rescue of murine silica-induced lung injury and fibrosis by human embryonic stem cells. Eur Respir J (2011) 1.53
The search for south European cystic fibrosis mutations: identification of two new mutations, four variants, and intronic sequences. Genomics (1991) 1.51
Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol (1999) 1.50
Posterior reversible encephalopathy syndrome in the Intensive Care Unit after liver transplant: a comparison of our experience with the existing literature. Minerva Anestesiol (2011) 1.49
Is protracted low-dose temozolomide feasible in glioma patients? Neurology (2006) 1.45
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. Cell Mol Life Sci (2005) 1.43
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology (2006) 1.42
Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. Neurology (1998) 1.42
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol (2001) 1.41
Individual haploinsufficient loci and the complex phenotype of DiGeorge syndrome. Mol Med Today (2000) 1.41
Prenatal diagnosis of triose phosphate isomerase deficiency. Lancet (1989) 1.40
Breast cancer detection with 99m-Tc-sestamibi scintigraphy, mammography, and fine-needle aspiration cytology: comparative study in 64 surgically treated patients. Ann Surg Oncol (1999) 1.40
99mTc-HMPAO SPECT in the diagnosis of brain death. Intensive Care Med (1998) 1.40
Analysis of 14 cystic fibrosis mutations in five south European populations. Hum Genet (1991) 1.40
Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy. Hum Mol Genet (1996) 1.39
Menstrual paroxysmal hemicrania, a possible new entity? Cephalalgia (2007) 1.38
Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum Mutat (1999) 1.37
A stop-codon mutation in the human mtDNA cytochrome c oxidase I gene disrupts the functional structure of complex IV. Am J Hum Genet (1999) 1.36
Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol (1993) 1.36
Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet (2009) 1.35
Detection of an atypical 7q11.23 deletion in Williams syndrome patients which does not include the STX1A and FZD3 genes. J Med Genet (1999) 1.35
Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve (1994) 1.34
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol (2008) 1.33
Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy. J Am Coll Cardiol (1995) 1.33
Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer (1997) 1.31
Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol (2005) 1.31
A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve (2000) 1.30
Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology (2004) 1.29
Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol (2001) 1.28
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol (2009) 1.27
Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol (2002) 1.27
Atypical deletions suggest five 22q11.2 critical regions related to the DiGeorge/velo-cardio-facial syndrome. Eur J Hum Genet (1999) 1.24
Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy. Hum Genet (1996) 1.24
Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis. Neuromuscul Disord (1997) 1.24
Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment? J Neuropathol Exp Neurol (2001) 1.21
A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. Hum Mol Genet (1996) 1.21
Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. Am J Hum Genet (1999) 1.21
Advantages of combined technetium-99m-sestamibi scintigraphy and high-resolution ultrasonography in parathyroid localization: comparative study in 91 patients with primary hyperparathyroidism. Eur J Endocrinol (2000) 1.20
Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology (2009) 1.20
The effects of long-term rehabilitation therapy on poststroke hemiplegic patients. Stroke (1993) 1.19
Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy. Neuromuscul Disord (1996) 1.19
Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry (2008) 1.19
TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol (2009) 1.18